Analyzing OraSure Technologies (OSUR) and Cardiovascular Systems (CSII)

OraSure Technologies (NASDAQ: OSUR) and Cardiovascular Systems (NASDAQ:CSII) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, institutional ownership, dividends, valuation and earnings.

Earnings and Valuation

This table compares OraSure Technologies and Cardiovascular Systems’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OraSure Technologies $167.06 million 6.53 $30.94 million $0.51 35.04
Cardiovascular Systems $204.91 million 5.20 -$1.79 million $0.03 1,068.67

OraSure Technologies has higher earnings, but lower revenue than Cardiovascular Systems. OraSure Technologies is trading at a lower price-to-earnings ratio than Cardiovascular Systems, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

OraSure Technologies has a beta of 1.68, indicating that its share price is 68% more volatile than the S&P 500. Comparatively, Cardiovascular Systems has a beta of 2.21, indicating that its share price is 121% more volatile than the S&P 500.

Profitability

This table compares OraSure Technologies and Cardiovascular Systems’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
OraSure Technologies 9.28% 6.58% 5.84%
Cardiovascular Systems -0.59% -1.03% -0.65%

Analyst Recommendations

This is a breakdown of current ratings and price targets for OraSure Technologies and Cardiovascular Systems, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OraSure Technologies 0 1 2 0 2.67
Cardiovascular Systems 1 4 1 0 2.00

OraSure Technologies presently has a consensus price target of $22.00, indicating a potential upside of 23.11%. Cardiovascular Systems has a consensus price target of $26.50, indicating a potential downside of 17.34%. Given OraSure Technologies’ stronger consensus rating and higher possible upside, equities analysts plainly believe OraSure Technologies is more favorable than Cardiovascular Systems.

Insider & Institutional Ownership

92.7% of OraSure Technologies shares are held by institutional investors. Comparatively, 81.1% of Cardiovascular Systems shares are held by institutional investors. 2.9% of OraSure Technologies shares are held by insiders. Comparatively, 3.3% of Cardiovascular Systems shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

OraSure Technologies beats Cardiovascular Systems on 10 of the 14 factors compared between the two stocks.

About OraSure Technologies

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Its principal products include OraQuick ADVANCE HIV-1/2, OraQuick HIV?1/2, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV, OraQuick Ebola, OraQuick Zika, OraSure QuickFlu Rapid Flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect DX, ORAcollect DNA, OMNIgene DISCOVER, Performagene, OMNIgene GUT, OMNIgene SPUTUM, OMNIgene VAGINAL, OMNIgene ORAL, GenoFIND, Hemagene, PrepIT, GenoFIND, Intercept, MICRO-PLATE DOA assays, Intercept i2, homogeneous DOA assays, and professional and over-the-counter cryosurgical systems. In addition, the company manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. Further, it provides medical devices for the removal of benign skin lesions by cryosurgery or freezing; immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, retail pharmacies, mass merchandisers, and consumers. OraSure Technologies, Inc. was founded in 1979 and is based in Bethlehem, Pennsylvania.

About Cardiovascular Systems

Cardiovascular Systems, Inc., a medical technology company, develops, manufactures, and markets devices to treat vascular diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 4 French 1.25 Peripheral OAS, Diamondback 360 1.50 Peripheral OAS, Diamondback 360 2.00 Peripheral OAS, and Stealth 360 Peripheral OAS, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives. It also provides Diamondback 360 Coronary OAS, an atherectomy device for the treatment of calcified coronary arteries. The company sells its products directly to hospitals or office-based labs. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in St. Paul, Minnesota.

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply